Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02296918 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | completed | Phase 1 | 69 | Acerta Pharma BVINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04913038 | Validation of the ANI in Perpubescent Patients in Pediatric Intensive Care Unit.(ANI-EP) | completed | — | 50 | University Hospital, LilleOTHER | 1 | Dec 19, 2025 |
| NCT05115630 | Off-the-shelf NK Cells + SCT for Myeloid Malignancies | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | completed | Phase 3 | 1,023 | Goethe UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06030089 | Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven(VENETACIBLE) | completed | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02005289 | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | completed | Phase 2 | 41 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02860676 | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | completed | Phase 1 | 3 | University of California, San DiegoOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04191187 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | completed | Phase 2 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT01869114 | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | completed | Phase 2 | 57 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02328014 | Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies | completed | Phase 1 / Phase 2 | 40 | Acerta Pharma BVINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT05923112 | BESPONSA Injection 1 mg Special Investigation | completed | — | 421 | PfizerINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | completed | Phase 3 | 371 | Astellas Pharma Global Development, Inc.INDUSTRY | 14 | Dec 4, 2025 | clinicaltrials |
| NCT05065866 | Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy | completed | Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03342196 | Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation | completed | Phase 2 | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03898128 | ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate(INO-CD22) | completed | — | 84 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05621148 | REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy(RESIST) | completed | — | 152 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05687032 | A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 4 | 44 | PfizerINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT00534469 | Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | completed | Phase 2 | 60 | City of Hope Medical CenterOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT02666898 | Phase II Trial GA101 Inbrutinib B CLL(ICLL07GAI) | completed | Phase 2 | 135 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06143839 | VYxeoS Liposomal Italian Observational Study iN the Real Practice(VYSION) | completed | — | 113 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02827617 | Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia | completed | — | 56 | Oncology Institute of Southern SwitzerlandOTHER | 2 | Nov 18, 2025 | clinicaltrials |
| NCT06882031 | Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia | completed | Phase 1 | 12 | SDK Therapeutics, Inc.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02996773 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | completed | Phase 1 | 50 | University of ArizonaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 445 | Hoffmann-La RocheINDUSTRY | 21 | Nov 6, 2025 | clinicaltrials |
| NCT02684162 | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant | completed | Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT06244147 | Long Term Safety and Efficacy of KSM-66 Ashwagandha in Adults | completed | — | 200 | SF Research Institute, Inc.NETWORK | 1 | Nov 6, 2025 | clinicaltrials |
| NCT07203885 | AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment(LEAP) | completed | N/A | 10 | Harvard Medical School (HMS and HSDM)OTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT01760655 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | completed | Phase 2 | 62 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04188678 | Resiliency in Older Adults Undergoing Bone Marrow Transplant(REBOUND) | completed | — | 126 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT02879643 | Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy | completed | Phase 1 | 29 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 22, 2025 | clinicaltrials |
| NCT00136435 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 20, 2025 | clinicaltrials |
| NCT01711632 | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
| NCT02512926 | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children(POE14-01) | completed | Phase 1 | 4 | Stanford UniversityOTHER | 2 | Oct 15, 2025 | clinicaltrials |
| NCT03118466 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 41 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03515512 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies(ELM-1) | completed | Phase 1 | 200 | Regeneron PharmaceuticalsINDUSTRY | 5 | Oct 10, 2025 | clinicaltrials |
| NCT04540796 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 147 | Janssen Research & Development, LLCINDUSTRY | 8 | Oct 10, 2025 | clinicaltrials |
| NCT03480438 | Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab(EWALL-BOLD) | completed | Phase 2 | 52 | Goethe UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT01316250 | Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia | completed | N/A | 13 | American University of Beirut Medical CenterOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04609826 | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)(DHODH) | completed | Phase 1 | 153 | Janssen Research & Development, LLCINDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT02356159 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2025source: clinicaltrials